February 2019 - An overview of NYGC's disease-based research focus, liquid biopsy, CRISPR gene editing, the Polyethnic-1000 project, single-cell analysis tools, and more:

On February 27, 2019, New York Genome Center (NYGC) Scientific Director and CEO Tom Maniatis, PhD, moderated a "Research Spotlight: The Future of Genomics" event for the MIT Enterprise Forum's New York chapter, with presentations by NYGC Core Faculty Members Dan Landau, MD, PhD, and Neville Sanjana, PhD, and NYGC staff scientists Nicolas Robine, PhD, and Eleni Mimitou, PhD. See more speaker presentation details below:

"NYGC’s Disease-Based Research Focus" - Tom Maniatis, PhD, Scientific Director and CEO, NYGC

"Liquid Biopsy Technology: Ultra-Sensitive Detection of Tumor DNA in the Blood for Dynamic Cancer Monitoring" - Dan Landau, MD, PhD, Core Faculty Member, NYGC; Assistant Professor of Medicine, Assistant Professor of Physiology and Biophysics, Weill Cornell Medicine

"Using CRISPR to Predict When Immunotherapy Will Fail in Cancer Patients" - Neville Sanjana, PhD, Core Faculty Member, NYGC; Assistant Professor of Biology, New York University Assistant Professor of Neuroscience and Physiology, NYU School of Medicine

"Polyethnic-1000: Multi-Ethnic Genomic Data Analysis To Advance Cancer Treatment for All Population Groups" - Nicolas Robine, PhD, Assistant Director, Computational Biology, NYGC

"CITE-seq & ECCITE-seq: New Genomic Techniques for Single Cell Analysis" - Eleni Mimitou, PhD, Senior Research Scientist,
Technology Innovation Lab, NYGC